- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06098846
Human Transdermal Vitamin D Supplement Study (TransVitD)
Double-Blind Placebo-Controlled Human Transdermal Vitamin D Supplement Study
Despite the wide availability of vitamin D supplements vitamin D deficiency remains a concerning global problem. It is hypothesised that hypothesize that vitamin D delivered via the skin will overcome the problems associated with variable oral bioavailability and lead to a patient-friendly and efficacious means to supplement this vitamin. The main objective of this study is therefore to test the efficacy of a vitamin D transdermal patch that employs vitamin D phosphate to deliver the vitamin D into the blood.
In this two-part supplementation study healthy individuals with a risk of vitamin D deficiency (n=118), aged between 18 - 65 years, will be recruited. The recruitment in central London, UK, will ensure a multicultural, multi-ethnic cohort to enable the findings to be translated into evidence to try and find a solution for the global vitamin D deficiency problem.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to understand the ability of a vitamin D transdermal patch to provide effective vitamin D supplementation. To do this, the study team will identify, using a questionnaire (validated collection tool), a cohort of healthy individuals who are at risk of vitamin D deficiency. The study team will take the personal details of the volunteers, a full medical history, food, exercise, body indices, and diet information and register these details. A baseline assessment will be taken of those patients who are identified by the questionnaire as likely to have low vitamin D levels and meet the study inclusion and exclusion criteria. The baseline measurements will include a blood sample to determine 25(OH)vitamin D3 (25(OH)VD3) concentration in the serum (perhaps also other metabolites), vitamin D binding protein (VDBP) concentrations in the blood serum and the skin interstitial fluid, parathyroid hormone levels and calcium in the blood. It will also require images of the human nails. This information will help to understand the vitamin D status of each study participant. This baseline data will be uploaded to a secure database and form the basic demographic information and baseline levels prior to the application of the vitamin D supplement patch.
The supplementation study will take 2 parts. In part one, two cohorts of 8 participants will be provided with one of two doses of the supplement in a dose escalation pilot study. These cohorts will be supplemented in sequence to establish the safety of the dose, with the lowest dose being confirmed to be safe prior to the second dose being tested. The primary outcome will be safety and tolerability. A calcium measure of more than 12 mg/dL or 25(OH)VD3 > 150 nM/L will indicate a risk of toxicity at the 2-week or 4-week blood draw and the dosing would terminate and this would be considered as a serious adverse event. If there are serious adverse events in 2 or more of the participants the dose will not be safe. The secondary outcome will be efficacy, and a change of 25(OH)VD3 of less than 5 nM/L in more than 75% of participants would indicate the dose is ineffective after 4 weeks and this will be used to guide the second cohort dosing.
Upon completion of part 1 the second part will begin. In part 2, the participants will be randomized by a statistician into 4 interventional arms, one placebo, and 3 different patch dosing frequencies. In part 2, the study will last 8 weeks with measurements at weeks 4 and 8. Part 2 will have an interim analysis at week 4, then it will proceed with only 2 study arms and make final measurements on week 8. The dosing for part 2 in the different arms of the study will be based on the part 1 results. The aim of these two studies is to establish if vitamin D supplementation via the skin improves the vitamin D status and at what dosing level/interval is required to achieve this.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stuart Jones, PhD
- Phone Number: 00442078484506
- Email: stuart.jones@kcl.ac.uk
Study Locations
-
-
-
London, United Kingdom, SE19NH
- Recruiting
- Institute of Pharmaceutical Science, King's College London
-
Contact:
- Stuart Jones
- Phone Number: 00442078484506
- Email: transvitd@kcl.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy adults between 18 and 65 years of age
- Suspected low vitamin D levels (defined as moderate or high risk using the Deschasaux questionnaire (10))
- Written informed consent for study participation.
- Willingness to comply with all study requirements.
- Competent use of English language.
Exclusion Criteria:
- Patients unable to give informed consent.
- The use of vitamin D supplements 4 weeks prior to the commencement of the study (and unwilling to washout).
- Pregnancy
- Those with parathyroid, thyroid, or calcium disorders, sarcoidosis, a requirement for calcium channel blockers, Type I diabetes, and concurrent active malignancies.
- Those who have been diagnosed with vitamin D deficiency by a GP in the last 3 months using a blood test.
- Those who have been diagnosed with vitamin D deficiency by a GP in the last 6 months using a blood test and have not taken any vitamin D supplements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo patch
Placebo transdermal patch daily
|
Application of a placebo transdermal patch
|
Active Comparator: Dose Frequency 1
Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
|
Application of a Vitamin D phosphate active patch
|
Active Comparator: Dose Frequency 2
Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
|
Application of a Vitamin D phosphate active patch
|
Active Comparator: Dose Frequency 3
Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
|
Application of a Vitamin D phosphate active patch
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of the change in 25(OH)vitamin D3 concentration in human serum compared to baseline
Time Frame: After 4 and 8 weeks compared to baseline
|
Concentration of 25(OH)vitamin in the serum (ng/ml)
|
After 4 and 8 weeks compared to baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of the change in vitamin D binding protein concentration in human serum compared to baseline
Time Frame: After 4 and 8 weeks compared to baseline
|
Concentration of vitamin D binding protein levels in the serum (micrograms per ml)
|
After 4 and 8 weeks compared to baseline
|
Measurement of chemical biomarker concentrations in the human skin interstitial fluid compared to baseline
Time Frame: 4 and 8 weeks compared to baseline
|
Concentration change of chemicals identified in skin interstitial fluid (ng/ml)
|
4 and 8 weeks compared to baseline
|
Measurement of the change in human nail plate characteristics measured using pixels compared to baseline
Time Frame: 4 and 8 weeks compared to baseline
|
Quantification of image feature change in nail photographs (unit pixels)
|
4 and 8 weeks compared to baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stuart Jones, King's College London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HR/DP-22/23-34078
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Supplementation
-
Boston Children's HospitalCompleted
-
Helsinki University Central HospitalUniversity of HelsinkiCompleted
-
Rajavithi HospitalCompletedPregnancy Outcome Among Vitamin D Supplementation During PregnancyThailand
-
University of AarhusNot yet recruitingImmune System Diseases | Growth | Child Development | Vitamin D Supplementation
-
Chulalongkorn UniversityUnknownVitamin D2 Supplementation in Vitamin D InsufficiencyThailand
-
University of AvignonCompletedDiabetes Complications | Vitamin D Deficiency | Vitamin D Supplementation | Myocardial DysfunctionFrance
-
Intermountain Health Care, Inc.USANA Health SciencesCompletedOsteoarthritis, Knee | Vitamin D Supplementation
-
Second Affiliated Hospital of Wenzhou Medical UniversityCompletedCrohn's Disease | Vitamin D Supplementation | Clinical Efficacy | UstekinumabChina
-
University of UlsterNorthern Ireland Executive; HSC Public Health AgencyCompletedVitamin D Status | Vitamin D ConcentrationUnited Kingdom
-
Society for Applied StudiesWorld Health OrganizationCompletedNeonatal Vitamin A SupplementationIndia
Clinical Trials on Placebo transdermal patch
-
The Cleveland ClinicTerminatedMild Cognitive Impairment | Mild Cognitive DisorderUnited States
-
Vibe G Frøkjær, MD, PhDHvidovre University Hospital; Herlev HospitalRecruiting
-
I.R.C.C.S. Fondazione Santa LuciaCompletedAlzheimer DiseaseItaly
-
Mundipharma Pte Ltd.Mundipharma Korea Ltd; Mundipharma (Hong Kong) Ltd; Mundipharma Distribution...CompletedOsteoarthritis | Rheumatoid Arthritis | Lower Back Pain | Joint Pain | Muscle PainHong Kong, Korea, Republic of, Philippines
-
Noven Pharmaceuticals, Inc.CompletedSchizophreniaUnited States
-
University of Colorado, DenverNational Institute on Aging (NIA)Not yet recruitingMenopause | Aging | Adiposity | Estrogen DeficiencyUnited States
-
Agile TherapeuticsCompleted
-
University of Illinois at ChicagoRecruitingSuicidal IdeationUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSuicidal IdeationUnited States
-
University of Colorado, DenverNational Institute on Aging (NIA)CompletedMenopause | Aging | Arterial StiffeningUnited States